| Adalimumab drug level | Median BWT | ||||||||||||
| IUS | MRI | ||||||||||||
| 4 months | 12 months | 12 months | |||||||||||
| n | Median (mm) | IQR (mm) | P value | n | Median (mm) | IQR (mm) | P value | Median (mm) | IQR (mm) | n | P value | ||
| 4 months a | ≤9.7 µg/L | 28 | 6.0 | 5.3-6.7 | .001 | 30 | 5.0 | 4.0-6.7 | .09 | 8.0 | 7.0-10 | 35 | .003 |
| > 9.7 µg/L | 31 | 4.5 | 3.1-5.7 | 31 | 4.3 | 3.0-5.7 | 6.0 | 3.0-8.0 | 34 | ||||
| 12 months b | ≤11.3 µg/L | 25 | 4.2 | 3.0-5.1 | .42 | 7.0 | 4.0-9.0 | 30 | .79 | ||||
| >11.3 µg/L | 28 | 5.2 | 3.0-6.1 | 7.0 | 4.0-9.0 | 31 | |||||||
| Adalimumab drug level | Median BWT | ||||||||||||
| IUS | MRI | ||||||||||||
| 4 months | 12 months | 12 months | |||||||||||
| n | Median (mm) | IQR (mm) | P value | n | Median (mm) | IQR (mm) | P value | Median (mm) | IQR (mm) | n | P value | ||
| 4 months a | ≤9.7 µg/L | 28 | 6.0 | 5.3-6.7 | .001 | 30 | 5.0 | 4.0-6.7 | .09 | 8.0 | 7.0-10 | 35 | .003 |
| > 9.7 µg/L | 31 | 4.5 | 3.1-5.7 | 31 | 4.3 | 3.0-5.7 | 6.0 | 3.0-8.0 | 34 | ||||
| 12 months b | ≤11.3 µg/L | 25 | 4.2 | 3.0-5.1 | .42 | 7.0 | 4.0-9.0 | 30 | .79 | ||||
| >11.3 µg/L | 28 | 5.2 | 3.0-6.1 | 7.0 | 4.0-9.0 | 31 | |||||||
aAll patients at 4 months were on 40 mg adalimumab fortnightly.
bPatients with active inflammation at 4 and/or 8 months (CRP, fecal calprotectin, and/or IUS) were dose escalated to 40 mg or 80 mg weekly.
Abbreviations: BWT, bowel wall thickness; IQR, interquartile range; IUS, intestinal ultrasound; MRI, magnetic resonance imaging.
| Adalimumab drug level | Median BWT | ||||||||||||
| IUS | MRI | ||||||||||||
| 4 months | 12 months | 12 months | |||||||||||
| n | Median (mm) | IQR (mm) | P value | n | Median (mm) | IQR (mm) | P value | Median (mm) | IQR (mm) | n | P value | ||
| 4 months a | ≤9.7 µg/L | 28 | 6.0 | 5.3-6.7 | .001 | 30 | 5.0 | 4.0-6.7 | .09 | 8.0 | 7.0-10 | 35 | .003 |
| > 9.7 µg/L | 31 | 4.5 | 3.1-5.7 | 31 | 4.3 | 3.0-5.7 | 6.0 | 3.0-8.0 | 34 | ||||
| 12 months b | ≤11.3 µg/L | 25 | 4.2 | 3.0-5.1 | .42 | 7.0 | 4.0-9.0 | 30 | .79 | ||||
| >11.3 µg/L | 28 | 5.2 | 3.0-6.1 | 7.0 | 4.0-9.0 | 31 | |||||||
| Adalimumab drug level | Median BWT | ||||||||||||
| IUS | MRI | ||||||||||||
| 4 months | 12 months | 12 months | |||||||||||
| n | Median (mm) | IQR (mm) | P value | n | Median (mm) | IQR (mm) | P value | Median (mm) | IQR (mm) | n | P value | ||
| 4 months a | ≤9.7 µg/L | 28 | 6.0 | 5.3-6.7 | .001 | 30 | 5.0 | 4.0-6.7 | .09 | 8.0 | 7.0-10 | 35 | .003 |
| > 9.7 µg/L | 31 | 4.5 | 3.1-5.7 | 31 | 4.3 | 3.0-5.7 | 6.0 | 3.0-8.0 | 34 | ||||
| 12 months b | ≤11.3 µg/L | 25 | 4.2 | 3.0-5.1 | .42 | 7.0 | 4.0-9.0 | 30 | .79 | ||||
| >11.3 µg/L | 28 | 5.2 | 3.0-6.1 | 7.0 | 4.0-9.0 | 31 | |||||||
aAll patients at 4 months were on 40 mg adalimumab fortnightly.
bPatients with active inflammation at 4 and/or 8 months (CRP, fecal calprotectin, and/or IUS) were dose escalated to 40 mg or 80 mg weekly.
Abbreviations: BWT, bowel wall thickness; IQR, interquartile range; IUS, intestinal ultrasound; MRI, magnetic resonance imaging.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
